Selected research
Industry Growth & Trends
Global Antibody Drug Conjugates (ADCs) Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Antibody Drug Conjugates (ADCs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Antibody Drug Conjugates (ADCs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Antibody Drug Conjugates (ADCs) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Antibody Drug Conjugates (ADCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Antibody Drug Conjugates (ADCs) market include AbGenomics, ADC Therapeutics, Astellas Pharma, Genmab, Kairos Therapeutics, Seattle Genetics, Takeda Pharmaceuticals, AbbVie and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Antibody Drug Conjugates (ADCs) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Antibody Drug Conjugates (ADCs) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antibody Drug Conjugates (ADCs) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antibody Drug Conjugates (ADCs).
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Antibody Drug Conjugates (ADCs) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Antibody Drug Conjugates (ADCs) Market by Company
AbGenomics
ADC Therapeutics
Astellas Pharma
Genmab
Kairos Therapeutics
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
Bayer
Pfizer
Roche
Novartis
Antibody Drug Conjugates (ADCs) Segment by Type
Seattle Genetics Technology
Immunomedics Technology
ImmunoGen Technology
Antibody Drug Conjugates (ADCs) Segment by Application
Hospital
Clinics
Others
Antibody Drug Conjugates (ADCs) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Drug Conjugates (ADCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody Drug Conjugates (ADCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Drug Conjugates (ADCs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Antibody Drug Conjugates (ADCs) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Seattle Genetics Technology
- Immunomedics Technology
- ImmunoGen Technology
Applications
- Hospital
- Clinics
- Others
Companies covered
- AbGenomics
- ADC Therapeutics
- Astellas Pharma
- Genmab
- Kairos Therapeutics
- Seattle Genetics
- Takeda Pharmaceuticals
- AbbVie
- Bayer
- Pfizer
- Roche
- Novartis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Antibody Drug Conjugates (ADCs) Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Antibody Drug Conjugates (ADCs) Market Size by Region (2021-2032)
- 1.4.1 Global Antibody Drug Conjugates (ADCs) Market Size by Region (2021-2026)
- 1.4.2 Global Antibody Drug Conjugates (ADCs) Market Size by Region (2027-2032)
- 1.5 Key Regions Antibody Drug Conjugates (ADCs) Market Size (2021-2032)
- 1.5.1 North America Antibody Drug Conjugates (ADCs) Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Antibody Drug Conjugates (ADCs) Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size Growth Rate (2021-2032)
- 1.5.4 South America Antibody Drug Conjugates (ADCs) Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size Growth Rate (2021-2032)
2 Antibody Drug Conjugates (ADCs) Market by Type
- 2.1 Type Introduction
- 2.1.1 Seattle Genetics Technology
- 2.1.2 Immunomedics Technology
- 2.1.3 ImmunoGen Technology
- 2.2 Global Antibody Drug Conjugates (ADCs) Market Size by Type
- 2.2.1 Global Antibody Drug Conjugates (ADCs) Market Size Overview by Type (2021-2032)
- 2.2.2 Global Antibody Drug Conjugates (ADCs) Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Antibody Drug Conjugates (ADCs) Market Size Forecasted by Type (2027-2032)
- 2.3 Global Antibody Drug Conjugates (ADCs) Market Size by Regions
- 2.3.1 North America Antibody Drug Conjugates (ADCs) Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Antibody Drug Conjugates (ADCs) Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Antibody Drug Conjugates (ADCs) Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Antibody Drug Conjugates (ADCs) Market Size Breakdown by Type (2021-2026)
3 Antibody Drug Conjugates (ADCs) Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Clinics
- 3.1.3 Others
- 3.2 Global Antibody Drug Conjugates (ADCs) Market Size by Application
- 3.2.1 Global Antibody Drug Conjugates (ADCs) Market Size Overview by Application (2021-2032)
- 3.2.2 Global Antibody Drug Conjugates (ADCs) Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Antibody Drug Conjugates (ADCs) Market Size Forecasted by Application (2027-2032)
- 3.3 Global Antibody Drug Conjugates (ADCs) Market Size by Regions
- 3.3.1 North America Antibody Drug Conjugates (ADCs) Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Antibody Drug Conjugates (ADCs) Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Antibody Drug Conjugates (ADCs) Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Antibody Drug Conjugates (ADCs) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Antibody Drug Conjugates (ADCs) Industry Trends
- 4.2 Antibody Drug Conjugates (ADCs) Industry Drivers
- 4.3 Antibody Drug Conjugates (ADCs) Industry Opportunities and Challenges
- 4.4 Antibody Drug Conjugates (ADCs) Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Antibody Drug Conjugates (ADCs) Revenue (2021-2026)
- 5.2 Global Antibody Drug Conjugates (ADCs) Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Antibody Drug Conjugates (ADCs) Key Company Headquarters & Area Served
- 5.4 Global Antibody Drug Conjugates (ADCs) Company, Product Type & Application
- 5.5 Global Antibody Drug Conjugates (ADCs) Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Antibody Drug Conjugates (ADCs) Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Antibody Drug Conjugates (ADCs) Players Market Share by Revenue in 2025
- 5.6.3 2025 Antibody Drug Conjugates (ADCs) Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 AbGenomics
- 6.1.1 AbGenomics Company Information
- 6.1.2 AbGenomics Business Overview
- 6.1.3 AbGenomics Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 AbGenomics Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.1.5 AbGenomics Recent Developments
- 6.2 ADC Therapeutics
- 6.2.1 ADC Therapeutics Company Information
- 6.2.2 ADC Therapeutics Business Overview
- 6.2.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 ADC Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.2.5 ADC Therapeutics Recent Developments
- 6.3 Astellas Pharma
- 6.3.1 Astellas Pharma Company Information
- 6.3.2 Astellas Pharma Business Overview
- 6.3.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Astellas Pharma Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.3.5 Astellas Pharma Recent Developments
- 6.4 Genmab
- 6.4.1 Genmab Company Information
- 6.4.2 Genmab Business Overview
- 6.4.3 Genmab Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Genmab Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.4.5 Genmab Recent Developments
- 6.5 Kairos Therapeutics
- 6.5.1 Kairos Therapeutics Company Information
- 6.5.2 Kairos Therapeutics Business Overview
- 6.5.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.5.5 Kairos Therapeutics Recent Developments
- 6.6 Seattle Genetics
- 6.6.1 Seattle Genetics Company Information
- 6.6.2 Seattle Genetics Business Overview
- 6.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Seattle Genetics Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.6.5 Seattle Genetics Recent Developments
- 6.7 Takeda Pharmaceuticals
- 6.7.1 Takeda Pharmaceuticals Company Information
- 6.7.2 Takeda Pharmaceuticals Business Overview
- 6.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.7.5 Takeda Pharmaceuticals Recent Developments
- 6.8 AbbVie
- 6.8.1 AbbVie Company Information
- 6.8.2 AbbVie Business Overview
- 6.8.3 AbbVie Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 AbbVie Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.8.5 AbbVie Recent Developments
- 6.9 Bayer
- 6.9.1 Bayer Company Information
- 6.9.2 Bayer Business Overview
- 6.9.3 Bayer Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Bayer Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.9.5 Bayer Recent Developments
- 6.10 Pfizer
- 6.10.1 Pfizer Company Information
- 6.10.2 Pfizer Business Overview
- 6.10.3 Pfizer Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Pfizer Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.10.5 Pfizer Recent Developments
- 6.11 Roche
- 6.11.1 Roche Company Information
- 6.11.2 Roche Business Overview
- 6.11.3 Roche Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Roche Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.11.5 Roche Recent Developments
- 6.12 Novartis
- 6.12.1 Novartis Company Information
- 6.12.2 Novartis Business Overview
- 6.12.3 Novartis Antibody Drug Conjugates (ADCs) Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Novartis Antibody Drug Conjugates (ADCs) Product Portfolio
- 6.12.5 Novartis Recent Developments
7 North America
- 7.1 North America Antibody Drug Conjugates (ADCs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
- 7.3 North America Antibody Drug Conjugates (ADCs) Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Antibody Drug Conjugates (ADCs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
- 8.3 Europe Antibody Drug Conjugates (ADCs) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Antibody Drug Conjugates (ADCs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
- 10.3 South America Antibody Drug Conjugates (ADCs) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst